These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 16863552)
1. Noninvasive markers of fibrosis for longitudinal assessment of fibrosis in chronic liver disease: are they ready for prime time? Thuluvath PJ; Krok KL Am J Gastroenterol; 2006 Jul; 101(7):1497-9. PubMed ID: 16863552 [TBL] [Abstract][Full Text] [Related]
2. Noninvasive markers of fibrosis for longitudinal assessment of fibrosis in chronic liver disease: are they ready for prime time? Thuluvath PJ; Krok KL Am J Gastroenterol; 2005 Sep; 100(9):1981-3. PubMed ID: 16128942 [TBL] [Abstract][Full Text] [Related]
3. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Poynard T; Zoulim F; Ratziu V; Degos F; Imbert-Bismut F; Deny P; Landais P; El Hasnaoui A; Slama A; Blin P; Thibault V; Parvaz P; Munteanu M; Trepo C Am J Gastroenterol; 2005 Sep; 100(9):1970-80. PubMed ID: 16128941 [TBL] [Abstract][Full Text] [Related]
4. The role of the non-invasive serum marker FibroTest-ActiTest in the prediction of histological stage of fibrosis and activity in children with naïve chronic hepatitis B infection. Sökücü S; Gökçe S; Güllüoğlu M; Aydoğan A; Celtik C; Durmaz O Scand J Infect Dis; 2010 Sep; 42(9):699-703. PubMed ID: 20429710 [TBL] [Abstract][Full Text] [Related]
5. Is serum alanine transaminase level a reliable marker of histological disease in chronic hepatitis C infection? Sanai FM; Benmousa A; Al-Hussaini H; Ashraf S; Alhafi O; Abdo AA; Alameri HF; Akbar HO; Bzeizi KI Liver Int; 2008 Aug; 28(7):1011-8. PubMed ID: 18384520 [TBL] [Abstract][Full Text] [Related]
6. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. Castera L J Viral Hepat; 2009 May; 16(5):300-14. PubMed ID: 19254351 [TBL] [Abstract][Full Text] [Related]
7. Non-invasive assessment of chronic liver and gastric diseases. Plebani M; Basso D Clin Chim Acta; 2007 May; 381(1):39-49. PubMed ID: 17374528 [TBL] [Abstract][Full Text] [Related]
8. Noninvasive markers of liver fibrosis and inflammation in chronic hepatitis B-virus related liver disease. Mohamadnejad M; Montazeri G; Fazlollahi A; Zamani F; Nasiri J; Nobakht H; Forouzanfar MH; Abedian S; Tavangar SM; Mohamadkhani A; Ghoujeghi F; Estakhri A; Nouri N; Farzadi Z; Najjari A; Malekzadeh R Am J Gastroenterol; 2006 Nov; 101(11):2537-45. PubMed ID: 17029616 [TBL] [Abstract][Full Text] [Related]
9. Prediction of liver fibrosis in patients with chronic hepatitis B by serum markers. Pan JJ; Yang CF; Chu CJ; Chang FY; Lee SD Hepatogastroenterology; 2007; 54(77):1503-6. PubMed ID: 17708285 [TBL] [Abstract][Full Text] [Related]
13. Predictive value of serum globulin levels for the extent of hepatic fibrosis in patients with chronic hepatitis B infection. Schmilovitz-Weiss H; Tovar A; Halpern M; Sulkes J; Braun M; Rotman Y; Tur-Kaspa R; Ben-Ari Z J Viral Hepat; 2006 Oct; 13(10):671-7. PubMed ID: 16970598 [TBL] [Abstract][Full Text] [Related]
14. Impact of quality control accepted inter-laboratory variations on calculated Fibrotest/Actitest scores for the non-invasive biochemical assessment of liver fibrosis. Gressner OA; Beer N; Jodlowski A; Gressner AM Clin Chim Acta; 2009 Nov; 409(1-2):90-5. PubMed ID: 19748500 [TBL] [Abstract][Full Text] [Related]
15. Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected haemophilia patients. Maor Y; Calès P; Bashari D; Kenet G; Lubetsky A; Luboshitz J; Schapiro JM; Pénaranda G; Bar-Meir S; Martinowitz U; Halfon P Haemophilia; 2007 Nov; 13(6):722-9. PubMed ID: 17973848 [TBL] [Abstract][Full Text] [Related]
16. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies. Bourliere M; Penaranda G; Renou C; Botta-Fridlund D; Tran A; Portal I; Lecomte L; Castellani P; Rosenthal-Allieri MA; Gerolami R; Ouzan D; Deydier R; Degott C; Halfon P J Viral Hepat; 2006 Oct; 13(10):659-70. PubMed ID: 16970597 [TBL] [Abstract][Full Text] [Related]
17. Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients. Zaman A; Rosen HR; Ingram K; Corless CL; Oh E; Smith K Am J Med; 2007 Mar; 120(3):280.e9-14. PubMed ID: 17349453 [TBL] [Abstract][Full Text] [Related]
18. Biomarkers of liver fibrosis. Adams LA J Gastroenterol Hepatol; 2011 May; 26(5):802-9. PubMed ID: 21198831 [TBL] [Abstract][Full Text] [Related]
19. Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. Tsochatzis E; Papatheodoridis GV; Hadziyannis E; Georgiou A; Kafiri G; Tiniakos DG; Manesis EK; Archimandritis AJ Scand J Gastroenterol; 2008; 43(9):1128-36. PubMed ID: 18609175 [TBL] [Abstract][Full Text] [Related]
20. Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases. Sebastiani G; Vario A; Guido M; Alberti A J Viral Hepat; 2008 Mar; 15(3):212-8. PubMed ID: 18179453 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]